New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:42 EDTIG, MNKMallinckrodt grants IGI Labs non-exclusive license to launch generic PENNSAID
IGI Laboratories (IG) announced that it has entered into an agreement with Mallinckrodt (MNK) and Nuvo Research to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application with the FDA seeking approval to market a generic version of PENNSAID 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7. IGI CEO Jason Grenfell-Gardner said, "The agreement provides IGI with a date certain launch of diclofenac sodium topical solution 1.5%. We remain confident in our ability to obtain final FDA approval of our ANDA for diclofenac sodium topical solution 1.5% prior to our agreed upon launch date. The agreement allows IGI to continue to expand its portfolio of generic topical prescription drug products."
News For IG;MNK From The Last 14 Days
Check below for free stories on IG;MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
09:06 EDTIGIGI Laboratories weakness a buying opportunity, says Craig-Hallum
Craig-Hallum recommends buying IGI Laboratories and is confident in the growth opportunities and expected ANDA approvals. Shares are Buy rated.
July 25, 2014
13:13 EDTMNKEinhorn bought Lam Research shares, sold Rite Aid last quarter
Subscribe for More Information
12:18 EDTMNKGreenlight discloses short positions in Safeway, Questcor, Bloomberg says
Subscribe for More Information
July 24, 2014
16:24 EDTIGIGI Laboratories reports Q2 EPS (1c), consensus 0c
Subscribe for More Information
16:22 EDTIGIGI Laboratories director Damian Finio resigns
IGI Laboratories has accepted Damian Finio's resignation from its Board of Directors effective August 11. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and will be unable to continue in his role as Director. The company has begun a search to replace Mr. Finio on its Board.
July 23, 2014
10:02 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMNKDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTMNKMallinckrodt initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
07:36 EDTMNKMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use